NCT07784959RecruitingPhase 1
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 20 Aug 2026
- Start date
- 17 Aug 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- Nuvectis Pharma, Inc.
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07784959
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 54
- From 17 Aug 2026 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)
Lab values
- Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
Who the study is looking for
- 18 years old or older
- Unresectable, metastatic or locally advanced ALK-positive NSCLC.
- Must have received lorlatinib as first or second line TKI
- One prior line of systemic chemotherapy is permitted
- Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NEXT Virginia Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.